156 related articles for article (PubMed ID: 33204076)
1. Marked Reduction in 28-day Mortality Among Elderly Patients with Severe Community-acquired Pneumonia: Post Hoc Analysis of a Large Randomized Controlled Trial.
Liu Y; Zhang C; Li C; Bai C; Shang H
Clin Interv Aging; 2020; 15():2109-2115. PubMed ID: 33204076
[TBL] [Abstract][Full Text] [Related]
2. XueBiJing Injection Versus Placebo for Critically Ill Patients With Severe Community-Acquired Pneumonia: A Randomized Controlled Trial.
Song Y; Yao C; Yao Y; Han H; Zhao X; Yu K; Liu L; Xu Y; Liu Z; Zhou Q; Wang Y; Ma Z; Zheng Y; Wu D; Tang Z; Zhang M; Pan S; Chai Y; Song Y; Zhang J; Pan L; Liu Y; Yu H; Yu X; Zhang H; Wang X; Du Z; Wan X; Tang Y; Tian Y; Zhu Y; Wang H; Yan X; Liu Z; Zhang B; Zhong N; Shang H; Bai C
Crit Care Med; 2019 Sep; 47(9):e735-e743. PubMed ID: 31162191
[TBL] [Abstract][Full Text] [Related]
3. Xuebijing injection in the treatment of severe pneumonia: study protocol for a randomized controlled trial.
Wang P; Song Y; Liu Z; Wang H; Zheng W; Liu S; Feng Z; Zhai J; Yao C; Ren M; Bai C; Shang H
Trials; 2016 Mar; 17(1):142. PubMed ID: 26983754
[TBL] [Abstract][Full Text] [Related]
4. Weaker Response to XueBiJing Treatment in Severe Community-Acquired Pneumonia Patients With Higher Body Mass Index or Hyperglycemia: A
Song Y; Wang X; Chen C; Wei T; Lang K; Yang D; Song Y
Front Pharmacol; 2022; 13():755536. PubMed ID: 35721170
[No Abstract] [Full Text] [Related]
5. Efficacy and safety of Xuebijing injection and its influence on immunomodulation in acute exacerbations of chronic obstructive pulmonary disease: study protocol for a randomized controlled trial.
Xie S; Yan P; Yao C; Yan X; Huo Y; Zhang J; Liu S; Feng Z; Shang H; Xie L
Trials; 2019 Feb; 20(1):136. PubMed ID: 30777117
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Xuebijing Injection () on Cardiopulmonary Bypass-Associated Pulmonary Injury: A Prospective, Single-center, Randomized, Double Blinded Trial.
Gao W; Li N; Cui XG
Chin J Integr Med; 2018 Nov; 24(11):815-821. PubMed ID: 30062633
[TBL] [Abstract][Full Text] [Related]
7. Effect of an Herbal-Based Injection on 28-Day Mortality in Patients With Sepsis: The EXIT-SEP Randomized Clinical Trial.
Liu S; Yao C; Xie J; Liu H; Wang H; Lin Z; Qin B; Wang D; Lu W; Ma X; Liu Y; Liu L; Zhang C; Xu L; Zheng R; Zhou F; Liu Z; Zhang G; Zhou L; Liu J; Fei A; Zhang G; Zhu Y; Qian K; Wang R; Liang Y; Duan M; Wu D; Sun R; Wang Y; Zhang X; Cao Q; Yang M; Jin M; Song Y; Huang L; Zhou F; Chen D; Liang Q; Qian C; Tang Z; Zhang Z; Feng Q; Peng Z; Sun R; Song Z; Sun Y; Chai Y; Zhou L; Cheng C; Li L; Yan X; Zhang J; Huang Y; Guo F; Li C; Yang Y; Shang H; Qiu H;
JAMA Intern Med; 2023 Jul; 183(7):647-655. PubMed ID: 37126332
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Xuebijing Injection for Sepsis (EXIT-SEP): protocol for a randomised controlled trial.
Liu S; Yao C; Zhang J; Yang Y; Qiu H;
BMJ Open; 2019 Aug; 9(8):e028664. PubMed ID: 31467049
[TBL] [Abstract][Full Text] [Related]
9. Curative effect of Xuebijing injection on severe pulmonary contusion.
Chen Y; Tong H; Zhang W; Zhang X; Pan Z; Qiu J; Pan R; Su L
J Tradit Chin Med; 2013 Dec; 33(6):743-51. PubMed ID: 24660605
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
11. [Xuebijing injection versus placebo for critically ill patients with severe community-acquired pneumonia: a randomized controlled trial: research results and clinical value].
Editorial Board Of Chinese Critical Care Medicine
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2019 Oct; 31(10):1199-1203. PubMed ID: 31771714
[TBL] [Abstract][Full Text] [Related]
12. The prediction of lymphocyte count and neutrophil count on the efficacy of Xuebijing adjuvant treatment for severe community-acquired pneumonia: A post hoc analysis of a randomized controlled trial.
Zhang C; He H; Chen X; Wei T; Yang C; Bi J; Tang X; Liu J; Zhang D; Chen C; Song Y; Miao C
Phytomedicine; 2023 Feb; 110():154614. PubMed ID: 36587417
[TBL] [Abstract][Full Text] [Related]
13. Xuebijing in the treatment of patients with sepsis.
Shi H; Hong Y; Qian J; Cai X; Chen S
Am J Emerg Med; 2017 Feb; 35(2):285-291. PubMed ID: 27852528
[TBL] [Abstract][Full Text] [Related]
14. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study.
Laterre PF; Garber G; Levy H; Wunderink R; Kinasewitz GT; Sollet JP; Maki DG; Bates B; Yan SC; Dhainaut JF;
Crit Care Med; 2005 May; 33(5):952-61. PubMed ID: 15891319
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of adjunctive corticosteroids therapy for patients with severe community-acquired pneumonia: A systematic review and meta-analysis.
Huang J; Guo J; Li H; Huang W; Zhang T
Medicine (Baltimore); 2019 Mar; 98(13):e14636. PubMed ID: 30921179
[TBL] [Abstract][Full Text] [Related]
16. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial.
Torres A; Sibila O; Ferrer M; Polverino E; Menendez R; Mensa J; Gabarrús A; Sellarés J; Restrepo MI; Anzueto A; Niederman MS; Agustí C
JAMA; 2015 Feb; 313(7):677-86. PubMed ID: 25688779
[TBL] [Abstract][Full Text] [Related]
17. Traditional chinese medicine Xuebijing treatment is associated with decreased mortality risk of patients with moderate paraquat poisoning.
Gong P; Lu Z; Xing J; Wang N; Zhang Y
PLoS One; 2015; 10(4):e0123504. PubMed ID: 25923333
[TBL] [Abstract][Full Text] [Related]
18. Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial.
Dinh A; Ropers J; Duran C; Davido B; Deconinck L; Matt M; Senard O; Lagrange A; Makhloufi S; Mellon G; de Lastours V; Bouchand F; Mathieu E; Kahn JE; Rouveix E; Grenet J; Dumoulin J; Chinet T; Pépin M; Delcey V; Diamantis S; Benhamou D; Vitrat V; Dombret MC; Renaud B; Perronne C; Claessens YE; Labarère J; Bedos JP; Aegerter P; Crémieux AC;
Lancet; 2021 Mar; 397(10280):1195-1203. PubMed ID: 33773631
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy of Chinese herbal injections for the treatment of community-acquired pneumonia: A Bayesian network meta-analysis of randomized controlled trials.
Huang X; Duan X; Zhu Y; Wang K; Wu J; Tian X
Phytomedicine; 2019 Oct; 63():153009. PubMed ID: 31301540
[TBL] [Abstract][Full Text] [Related]
20. Improving outcomes of elderly patients with community-acquired pneumonia.
Gutiérrez F; Masiá M
Drugs Aging; 2008; 25(7):585-610. PubMed ID: 18582147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
